Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future

Bibliography

• The importance of pharmacovigilance; safety monitoring of medicinal products. Geneva, World Health Organization, 2002
   Google Scholar
• Napoleone E. Children and ADRs (Adverse Drug Reactions). Int J Ped 2010;11:4
   Google Scholar
• Safety of Medicines. A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. Geneva, World Health Organization, 2002
   Google Scholar
• World Health Organization. Lexicon of alcohol and drug terms published by the World Health Organization. Available from: www.who.int/substance_abuse/terminology/who_lexicon/en. Accessed March 04, 2011
   Google Scholar
• Nebeker JR, Barach P, Samore MH. Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation, and Reporting. Ann Intern Med 2004;140:795-801
   PubMed Web of Science ®Google Scholar
• World Health Organization. Promoting safety of medicines for children. 2007. Available from: www.who.int/medicines/publications/essentialmedicines/Promotion_safe_med_children.pdf
   Google Scholar
• Available online from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Last access on 24th April 2011
   Google Scholar
• Available online from: http://eudravigilance.ema.europa.eu/highres.htm. Last access on 24th April 2011
   Google Scholar
• European Medicine Agency-Committee for Medicinal Product for Human Use (CHMP). Guideline on conduct of pharmacovigilance for medicines used by the paediatric population. London, 2007
   Google Scholar
• Available online from: http://www.ema.europa.eu. Last access on 24th April 2011
   Google Scholar
• ICH E 11 Clinical investigation of medicinal products in the paediatric population. Published in the UK in: EU: Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). London, 2000; and in the US in: US: International Conference on Harmonisation. Guidance on E 11 clinical investigation of medicinal products in pediatric population; Notice. Fed Regist 2000;65:78493-4
   PubMedGoogle Scholar
• Mulla H. Understanding developmental pharmacodynamics: importance for drug development and clinical practice. Pediatr Drugs 2010;12:223-33
   PubMedGoogle Scholar
• Fillman SG, Duncan CE, Webster MJ, Developmental co-regulation of the beta and gamma GABAA receptor subunits with distinct alpha subunits in the human dorsolateral prefrontal cortex. Int J Devl Neuroscience 2010;28:513-19
   PubMed Web of Science ®Google Scholar
• Ben-Ari Y. Seizures beget seizures: the quest for GABA as a key player. Crit Rev Neurobiol 2006;18:135-44
   PubMedGoogle Scholar
• Nandi R, Beachman D, Middleton J, The functional expression of mu opioid receptors on sensory neurons is developmentally regulated; morphine analgesia is less selective in the neonate. Pain 2004;111:38-50
   PubMed Web of Science ®Google Scholar
• Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clinical Pharmacol Ther 1999;66:66-75
   PubMed Web of Science ®Google Scholar
• Reinalter SC, Jeck N, Peters M, Seyberth HW. Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand 2004;181:513-21
   PubMedGoogle Scholar
• Agunod M, Yamaguchi N, Lopez R, Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969;14:400-14
   PubMedGoogle Scholar
• Rennie JM, Roberton NRC. Textbook of neonatology. Edinburgh: Churchill Livingstone, 3rd edition 1999
   Google Scholar
• Johnson PJ. Neonatal pharmacology-pharmacokinetics. Neonatal Netw 2011;30:54-61
   PubMedGoogle Scholar
• Huang NN, High RH. Comparison of serum levels following the administration of oral and pa- enteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953;6:57-68
   Google Scholar
• Morselli PL. Antiepileptic drugs. In: Morselli PL, ed. Drug disposition during development. New York: Spectrum, 1977:311-60
   Google Scholar
• Strolin-Benedetti M, Baltes EM. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003;17:281-99
   PubMed Web of Science ®Google Scholar
• Anderson BJ, van Lingen RA, Hansen TG, Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 2002;96:1336-45
   PubMed Web of Science ®Google Scholar
• Tetelbaum M, Finkelstein Y, Nava-Ocampo A, Back to basics: Understanding drugs in children: Pharmacokinetic maturation. Pediatr Rev 2005;26:321-8
   PubMed Web of Science ®Google Scholar
• Routledge PA. Pharmacokinetics in children. J Antimicrob Chemother 1994;34:19-24
   PubMed Web of Science ®Google Scholar
• Lugo R, Ward R. Basic pharmacokinetic principles. In: Polin R, Fox W, Abman S, editors, Fetal and neonatal physiology. 3rd edition. Harcourt Health Sciences, Philadelphia; 2004. p. 190-7
   Google Scholar
• Touw DJ, Graafland O, Cranendonk A, Clinical pharmacokinetics of phenobarbital in neonates. Eur J Pharm Sci 2000;12:111-16
   PubMed Web of Science ®Google Scholar
• Alfonso IALA, Gilman J, Gilman T, Intravenous valproate dosing in neonates. J Child Neurol 2000;15:827-9
   PubMed Web of Science ®Google Scholar
• Mazoit JX. Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications. Pediatr Drugs 2006;8:139-50
   PubMedGoogle Scholar
• Ehrnebo M, Agurell S, Jalling B, Boreus LO. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. J Eur Clin Pharmacol 1971;3:189-93
   PubMed Web of Science ®Google Scholar
• Windorfer A, Kuenzer W, Urbanek R. The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding. Eur J Clin Pharmacol 1974;7:227-31
   PubMed Web of Science ®Google Scholar
• Kurz H, Michels H, Stickel HH. Differences in the binding of drugs to plasma proteins from newborn to adult man. Eur J Clin Pharmacol 1977;11:469-72
   PubMed Web of Science ®Google Scholar
• Vieira I, Sonnier M, Cresteil T. Developmental expression of CYP2E1 in the human liver: hypermethylation control of gene expression during the neonatal period. Eur J Biochem 1996;238:476-83
   PubMedGoogle Scholar
• Treluyer J-M, Jacqz-Aigrain E, Alvarez F, Cresteil T. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991;202:583-88
   PubMedGoogle Scholar
• Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998;251:893-98
   PubMedGoogle Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67
   PubMed Web of Science ®Google Scholar
• Wildt SN, Kearns GL, Leeder JS, Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505
   PubMed Web of Science ®Google Scholar
• Wildt SN, Kearns GL, Leeder JS, Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999;36:439-43
   PubMed Web of Science ®Google Scholar
• Murry DJ, Crom WR, Reddick WE, Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995;23:1110-16
   PubMed Web of Science ®Google Scholar
• Kanamori M, Takahaski H, Echizen H, Developmental changes in the liver weight- and body-weight normalized clearance of theophylline, phenytoine and cyclosporine in children. Int J Clin Pharmacol Ther 2002;40:485-92
   PubMed Web of Science ®Google Scholar
• Robillard JE, Guillery EN, Petershack JA. Renal function during fetal life. In: Barratt TM, Avner ED, Harmon WE, eds. Pediatric nephrology. 4th edition. Baltimore: Lippincott Williams & Wilkins 1999:21-37
   Google Scholar
• Routledge PA. Pharmacokinetics in children. J. Antimicrob Chemother 1994;34:19-24
   Web of Science ®Google Scholar
• Bird NJ, Henderson BL, Lui D, Indexing glomerular filtration rate to suit children. J Nucl Med 2003;44:1037-44
   PubMed Web of Science ®Google Scholar
• Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS Pharm Sci 2002;2:e3
   Google Scholar
• Neville KA, Becker ML, Glodman JL, Developmental pharmacogenomics. Pedatr Anesth 2011;21:255-65
   PubMed Web of Science ®Google Scholar
• Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008;118:250-67
   PubMed Web of Science ®Google Scholar
• Hines RN, Koukouritaki SB, Poch MT, Regulatory polymorphism and their contribution to interindividual differences in the expression of enzymes influencing drug and toxicant disposition. Drug Metab Rev 2008;40:263-301
   PubMed Web of Science ®Google Scholar
• Trevino LR, Sjimasaki N, Yang W, Germline genetic variation in an organic anion transporter polypeptyde associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009;27:5972-78
   PubMed Web of Science ®Google Scholar
• Gilman JT. Therapeutic drug monitoring in the neonate and paediatric age group – problems and clinical pharmacokinetic implications. Clin pharmacokin 1990;19:1-10
   PubMed Web of Science ®Google Scholar
• Burns JP. Research in children. Crit Care Med 2003;31(Suppl 3):S131-6
   PubMed Web of Science ®Google Scholar
• Conroy S, McIntyre J, Choonara I, Drug trials in children: problems and the way forward. Br J Clin Pharmacol 2000;49:93-97
   PubMed Web of Science ®Google Scholar
• Conroy S, Choonara I, Impicciatore I, Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. Br Med J 2000;320:79-82
   PubMed Web of Science ®Google Scholar
• Schirm E, Tobi H, Jong-Van D, den Berg LTW. Unlicensed and off label drug use by children in the community: cross sectional study. BMJ 2002;324:1312-13
   PubMed Web of Science ®Google Scholar
• Pandolfini C, Campi R, Clavenna A, Italian paediatricians and off-label prescriptions: loyal to regulatory or guideline standards? Acta Paediatr 2005;94:753-57
   PubMed Web of Science ®Google Scholar
• Conroy S, Carroll WD. Prescribing in pediatrics. Arch Dis Child Educ Pract 2009;94:55-9
   PubMedGoogle Scholar
• Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005;164:552-58
   PubMed Web of Science ®Google Scholar
• Conroy S, McIntre J, Choonora I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999;80:F142-4
   PubMed Web of Science ®Google Scholar
• Dall'Aera M, Gasbarro AR, Padovano M, Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci 2007;29:361-7
   PubMed Web of Science ®Google Scholar
• Avenel S, Bomkratz A, Dassieu G, The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr 2000;7:143-7
   PubMed Web of Science ®Google Scholar
• O'Donnell CP, Stone RS, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002;110(5):e52
   PubMedGoogle Scholar
• ‘t Jong GW, Vulto AG, de Hoog M, A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 2001;108:1089-93
   PubMed Web of Science ®Google Scholar
• Dessì A, Salemi C, Fanos V, Cuzzolin L. Drug treatments in a neonatal setting: focus on the off-label use in the first month of life. Pharm World Sci 2010;32:120-4
   PubMed Web of Science ®Google Scholar
• Neubert A, Lukas K, Leis T, Drug utilization on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol 2010;66:87-95
   PubMed Web of Science ®Google Scholar
• Porta A, Esposito S, Menson E, Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol 2010;66:919-27
   PubMed Web of Science ®Google Scholar
• Choonara I, Conroy S. Unlicensed and off-label drug use in children. Implications for safety. Drug safety 2002;25:1-5
   PubMed Web of Science ®Google Scholar
• Gill AM, Leach HJ, Hughes J, Adverse drug reactions in a paediatric intensive care unit. Acta Paediatr 1995;84:438-41
   PubMed Web of Science ®Google Scholar
• Turner S, Nunn AJ, Fielding K, Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999;88:965-8
   PubMed Web of Science ®Google Scholar
• Clarkson A, Ingleby E, Choonara I, A novel scheme for the reporting of adverse drug reactions. Arch Dis Child 2001;84:337-9
   PubMed Web of Science ®Google Scholar
• Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006;5:703-18
   PubMed Web of Science ®Google Scholar
• Impicciatore P, Choonara I, Clarkson A, Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001;52:77-83
   PubMed Web of Science ®Google Scholar
• Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child 2009;94:724-8
   PubMed Web of Science ®Google Scholar
• Moore TJ, Weiss RS, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002;110:e53
   PubMed Web of Science ®Google Scholar
• Kimland E, Rane A, Ufer M, Panagiotidis G. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf 2005;14:493-9
   PubMed Web of Science ®Google Scholar
• Le J, Nguyen T, Law AV, Hodding J. Adverse drug reactions among children over a 10-year period. Pediatrics 2006;118:555-62
   PubMed Web of Science ®Google Scholar
• Carleton BC, Smith MA, Gelin MN, Heathcote SC. Paediatric adverse drug reaction reporting: understanding and future directions. Can J Clin Pharmacol 2007;14:e45-57
   PubMedGoogle Scholar
• Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark. A retrospective analysis of reports to the Danish Medicine Agency from 1998 to 2007. Drug Saf 2010;33:327-39
   PubMed Web of Science ®Google Scholar
• AIFA-Ministero della Salute. Bollettino d'Informazione sui Farmaci (BIF) XIII 2006:5;210-14
   Google Scholar
• Moore TJ, Weiss SR, Blaisdell CR. Reported fatal and serious adverse reactions associated with palivizumab [abstract]. Pediatr Acad Soc 2002. Available from: http://www.pas-meeting.org/2002baltimore/latebreaker_files/lbabstracts.htm#7062. Accessed March 20, 2011
   Google Scholar
• Bourgeois FT, Mandl KD, Valim C, Shannon MW. Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics 2009;124:e744-50
   PubMed Web of Science ®Google Scholar
• Shinomiya K, Kajima M, Tajika H, Renal failure caused by eyedrops containing phenylephrine in a case of retinopathy of prematurity. J Med Invest 2003;50:203-06
   PubMedGoogle Scholar
• Alpay A, Ermis B, Ugurbas SC, The local vasoconstriction of infant's skin following instillation of mydriatic eye drops. Eur J Clin Pharmacol 2010;66:1161-4
   PubMed Web of Science ®Google Scholar
• Meyburg J, Kolker S, Hoffmann GF, Zilow E. Coma in neonates following nasal decongestant drops? Deutsches Arzteblatt 2006;103A:3411-13
   Google Scholar
• Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001;6:63-73
   PubMedGoogle Scholar
• Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2005;19:CD003481
   Google Scholar
• Ahlfors CE, Wennberg RP. Bilirubin-albumin binding and neonatal jaundice. Semin Perinatol 2004;28:334-9
   PubMed Web of Science ®Google Scholar
• Marshall BC, Koch WC. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Pediatr Drugs 2009;11:309-21
   PubMedGoogle Scholar
• Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes 2010;11:142-7
   PubMed Web of Science ®Google Scholar
• Holmes LB. Human teratogens: Update 2010. Birth Defects Res 2011;91:1-7
   PubMed Web of Science ®Google Scholar
• Costei AM, Kozer E, Ho T, Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Coombs RC, Isbister GK. Paroxetine withdrawal in a neonate with historical and laboratory confirmation. Eur J Pediatr 2003;162:723-4
   PubMed Web of Science ®Google Scholar
• Sanz EJ, De-las-Cuevas C, Kiuru A, Selective serotonine reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-7
   PubMed Web of Science ®Google Scholar
• Ahmed M, Parameshwaran A, Swamy P. Neonatal convulsions secondary to paroxetine withdrawal. J Pak Med Assoc 2007;57:162
   PubMedGoogle Scholar
• Murray KL, Miller KM, Pearson DL. Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine. J Perinatol 2007;27:517-18
   PubMed Web of Science ®Google Scholar
• Pogliani L, Schneider L, Dilillo D, Paroxetine and neonatal withdrawal syndrome. BMJ Case Reports 2010; doi:10.1136/bcr.12.2009.2528
   Google Scholar
• Saulnier PJ, Piguel X, Perault-Pochat MC, Hypoglycaemic seizure and neonatal acute adrenal insufficiency after maternal exposure to prednisone during pregnancy: a case report. Eur J Pediatr 2010;169:763-65
   PubMed Web of Science ®Google Scholar
• Shirkey HC. Therapeutic orphans – everybody's business. Ann Pharmacother 2006;40:1174
   PubMed Web of Science ®Google Scholar
• Kalikstad B, Skjerdal A, Hansen TWR. Compatibility of drug infusions in the NICU. Arch Dis Child 2010;95:745-8
   PubMed Web of Science ®Google Scholar
• Bradley JS, Wassel RT, Lee L, Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 2009;123:e609-13
   PubMed Web of Science ®Google Scholar
• Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000;106(Suppl):S128-38
   PubMedGoogle Scholar
• MacLeod S. Therapeutic Drug Monitoring in Pediatrics: How Do Children Differ? Ther Drug Monit 2010;32:253-6
   PubMed Web of Science ®Google Scholar
• Wong IC, Galeb MA, Franklin BD, Incidence and nature of dosing errors in paediatric medications—a systematic review. Drug Safety 2004;27:661-70
   PubMed Web of Science ®Google Scholar
• Ross LM, Wallace J, Paton JY. Medication errors in a paediatric teaching hospital in the UK: five years operational experience. Arch Dis Child 2000;83(6):492-7
   PubMed Web of Science ®Google Scholar
• Raju TN, Kecskes S, Thornton JP, Medication errors in neonatal and paediatric intensive-care units. Lancet 1989;2:374-6
   PubMed Web of Science ®Google Scholar
• Vincer MJ, Murray JM, Yuill A, Drug errors and incidents in a neonatal intensive care unit. A quality assurance activity. Am J Dis Child 1989;143:737-40
   PubMedGoogle Scholar
• Chedoe I, Molendijk HA, Dittrich ST, Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature. Drug Saf 2007;30:503-13
   PubMed Web of Science ®Google Scholar
• AIFA-Ministero della Salute. Bollettino d'Informazione sui Farmaci (BIF) XVI 2009:1;24-8
   Google Scholar
• Fabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: Remember the excipients. Pharmacol Res 2011; doi:10.1016/j.phrs.2011.01.006
   Google Scholar
• Zuccotti GV, Fabiano V. Safety issues with ethanol as an excipient in drugs intended for pediatric use. Exp Opin Drug Saf 2011; doi:10.1517/14740338.2011.565328
   Google Scholar
• Vallano A, Cereza G, Pedros C, Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol 2005;60:653-8
   PubMed Web of Science ®Google Scholar
• Eland IA, Belton KJ, van Grootheest AC, Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999;48:623-7
   PubMed Web of Science ®Google Scholar
• Ball D, Tisocki T. Adverse drug reaction reporting by general medical practitioners and retail pharmacists in Harare – a pilot study. Cent Afr J Med 1998;44:190-5
   PubMedGoogle Scholar
• Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004;140:795-801
   PubMed Web of Science ®Google Scholar
• Kaletra (lopinavir/ritonavir): Label Change – Serious Health Problems in Premature Babies. Available online from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm246167.htm (Accessed on 2011 March, 21)
   Google Scholar
• Clarkson A, Conroy S, Burroughs K, Choonara I. Surveillance for adverse drug reactions in children: a paediatric regional monitoring centre. Paediatr Perinat Drug Ther 2004;6:20-3
   Google Scholar
• Dormann H, Muth-Selbach U, Krebs S, Incidence and costs of adverse drug reactions during hospitalization: computerized monitoring versus stimulated spontaneous reporting. Drug Saf 2000;22:161-8
   PubMed Web of Science ®Google Scholar
• Honigman B, Light P, Pulling RM, Bates DW. A computerized method for identifying incidents associated with adverse drug events in outpatients. Int J Med Inf 2001;61:21-32
   PubMed Web of Science ®Google Scholar
• Weiss J, Krebs S, Hoffmann C, Survey of adverse drug reactions on a pediatric ward: a strategy for early and detailed detection. Pediatrics 2002;110:254-7
   PubMed Web of Science ®Google Scholar
• Neubert A, Dormann H, Weiss J, Are computerized monitoring systems of value to improve pharmacovigilance in paediatric patients? Eur J Clin Pharmacol 2006;62:959-65
   PubMed Web of Science ®Google Scholar
• van Puijenbroek E, Conemans J, van Grootheest K. Spontaneous ADR Reports as a Trigger for Pharmacogenetic Research. A prospective observational study in the Netherlands. Drug Safety 2009;32:255-64
   PubMed Web of Science ®Google Scholar
• Howland RH. Pharmacogenetics and Pharmacovigilance. Drug Safety 2009;32:265-70
   PubMed Web of Science ®Google Scholar
• Loo TT, Ross CJD, Sistonen J, Pharmacogenomics and active surveillance for serious adverse drug reactions in children. Pharmacogenomics 2010;11:1269-85
   PubMed Web of Science ®Google Scholar
• Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281:824-9
   PubMed Web of Science ®Google Scholar
• de Vries WT, van Roon EN. Low quality of reporting adverse drug reactions in paediatric randomized controlled trials. Arch Dis Child 2010;95:1023-6
   PubMed Web of Science ®Google Scholar
• Castro-Pastrana LI, Carleton BC. Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. J Popul Ther Clin Pharmacol 2011;18:e76-88
   PubMedGoogle Scholar